Clinical Data, Inc. announced that its Cogenics Division, a provider of pharmacogenomics and molecular biology services, has chosen the Radius automation system produced by Protedyne Corporation to increase throughput and capacity to meet the needs of its growing client base in its Quantitative PCR and CLIA sequencing offerings.
“With our continued focus on revenue growth, cost reductions and our commitment to investment in our strategic businesses, we are incorporating Protedyne’s Radius robotic systems into our CLIA sequencing and Quantitative PCR franchises. This new equipment is required for the higher throughput studies that our clients are demanding,” stated Dr. Robert Bondaryk, Cogenics General Manager.
“Our clients are tasking us with ever larger projects for their QPCR and clinical diagnostic application based studies. We are meeting this increased demand and complexity by, in part, incorporating the Radius automation system. This platform strongly supports current tests such as Familion Long QT and the continuing rollout of new CLIA sequencing tests launched by Clinical Data’s PGxHealth Division,” Dr. Bondaryk continued.
The Radius is a sophisticated benchtop automation platform designed with an ingenious radial arm to provide the highest level of flexibility built to ensure reliability, superior speed, and unmatched precision.
“We are very pleased that Cogenics has elected to automate their sequencing and Q-PCR assays on Radius,” said Pete Massaro, Chief Technology Officer of Protedyne.
“Cogenics is exactly the type of customer we envisioned when we developed our Radius platform, and I am confident that this system will provide the reliability and throughput required to meet current and future goals.”